Current Report Filing (8-k)
May 26 2020 - 07:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 26,
2020
ZYNERBA
PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
|
Delaware |
|
001-37526 |
|
26-0389433 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8–K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17
CFR 240.14a–12)
¨ Pre–commencement
communications pursuant to Rule 14d–2(b) under the
Exchange Act (17 CFR 240.14d–2(b))
¨ Pre–commencement
communications pursuant to Rule 13e–4(c) under the
Exchange Act (17 CFR 240.13e–4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.001 par value per
share |
|
ZYNE |
|
The
NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. x
Item 8.01 Other Events
On May 26, 2020, Zynerba Pharmaceuticals, Inc. (the
“Company”) issued a press release announcing that it has had
a poster titled “Cannabidiol Transdermal Gel for the Treatment of
Fragile X Syndrome: Post Hoc Analysis of FAB-C and Pattern of
Efficacy on Domains of the Aberrant Behavior Checklist-Community
for FXS (ABC-CFXS) Through 116 Weeks of Treatment”
accepted for inclusion on the American Academy of Neurology
(“AAN”) annual meeting virtual platform.
On May 26, 2020, the Company issued a second press release
announcing that it has had two additional posters accepted for
inclusion on the AAN annual meeting virtual platform titled:
|
· |
“Cannabidiol Transdermal Gel in Children and Adolescents with
Developmental and Epileptic Encephalopathies: An Open-Label
Clinical Trial (BELIEVE)”; and |
|
· |
“Quality of Life and Qualitative Caregiver Assessments in
Children and Adolescents with Developmental and Epileptic
Encephalopathies Treated With Cannabidiol Transdermal Gel: An
Open-Label Clinical Trial (BELIEVE)”. |
Copies of the two press releases are attached hereto as Exhibits
99.1 and 99.2 and incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits
(d) Exhibits
* Filed herewith
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: May 26, 2020
| |
ZYNERBA
PHARMACEUTICALS, INC. |
| |
|
| |
By: |
/s/
Suzanne Hanlon |
| |
|
Name:
Suzanne Hanlon |
| |
|
Title:
Secretary, Vice President and General Counsel |
